TIDMDDDD

RNS Number : 5288A

4d Pharma PLC

30 May 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

 
 Name                           Shares in   % of total    Shares in   % of total 
                                4D pharma    shares in    4D pharma    shares in 
                               plc before        issue    plc after        issue 
                                 purchase                  purchase 
 
 David Norwood (Chairman)       7,108,725       10.85%    7,123,725       10.88% 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                            David Norwood 
     ------------------------------  -------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------- 
 a)   Position/status                 PDMR 
     ------------------------------  -------------------------------- 
 b)   Initial notification            Initial notification 
       /Amendment 
     ------------------------------  -------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------- 
 a)   Name                            4D Pharma plc 
     ------------------------------  -------------------------------- 
 b)   LEI                             213800O49VYSXWE2ZD52 
     ------------------------------  -------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------- 
 a)   Description of the              Ordinary shares of GBP0.0025 
       financial instrument,           ISIN: GB00BJL5BR07 
       type of instrument 
       Identification code 
     ------------------------------  -------------------------------- 
 b)   Nature of the transaction       Purchase of Ordinary Shares 
     ------------------------------  -------------------------------- 
 c)   Price(s) and volume(s)            Price(s)   Volume(s) 
                                         100p       15,000 
                                                   ---------- 
     ------------------------------  -------------------------------- 
 d)   Aggregated information 
       - Aggregated volume              N/A 
       - Price 
     ------------------------------  -------------------------------- 
 e)   Date of the transaction         29(th) May 2019 
     ------------------------------  -------------------------------- 
 f)   Place of the transaction        London Stock Exchange, AIM 
     ------------------------------  -------------------------------- 
 
 
 
 
 

For further information please contact:

 
4D 
Duncan Peyton, Chief Executive Officer         + 44 (0)113 895 0130 
 Fay Weston, Head of Investor Relations         + 44 (0)7990 381713 
Zeus Capital Limited - Nomad and Joint Broker  +44 (0)161 831 1512 
Dan Bate / Jordan Warburton 
Bryan Garnier & Co. Limited - Joint Broker     +44 (0)20 7332 2500 
Dominic Wilson 
 Phil Walker 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAKSNAAKNEFF

(END) Dow Jones Newswires

May 30, 2019 02:01 ET (06:01 GMT)

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di 4d Pharma
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di 4d Pharma